CorpBanca Schedules Second Quarter 2014 Financial Results,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CorpBanca Schedules Second Quarter 2014 Financial Results, Conference Call and Webcast

SANTIAGO, CHILE--(Marketwired - Jul 30, 2014) - CORPBANCA ( NYSE : BCA ) ( SSE : CORPBANCA ) announced today that it will release its results for the second quarter ended June 30, 2014 after the market closes in New York on Tuesday, August 12, 2014.

On Wednesday, August 13, 2014, at 10:00 A.M. ET, the Company's management team will host a conference call to discuss the financial results. The call will be hosted by Fernando Massú, CorpBanca's Chief Executive Officer, Eugenio Gigogne, CorpBanca's Chief Financial Officer, and Claudia Labbé, CorpBanca's Head of Investor Relations.

Conference Call Details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (866) 819-7111 (US Toll Free Dial In), 0(800) 953-0329 (UK Toll Free Dial In) or +44 (0)1452-542-301 (Standard International Dial In). Please quote "CorpBanca" to the operator.

A telephonic replay of the conference call will be available until August 20, 2014 by dialing 1 (866) 247-4222 (US Toll Free Dial In), 0(800) 953-1533 (UK Toll Free Dial In) or +44 (0)1452 550-000 (Standard International Dial In). Access Code: 2339939#

Slides and Audio Webcast:

There will also be a live, and then archived, webcast of the conference call, available through the Company's website. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. The webcast can be found at http://corpbanca.irwebpage.com/webcast_2014-2Q.html

About CorpBanca

CORPBANCA ( NYSE : BCA ) ( SSE : CORPBANCA ) is Chile's oldest operating private bank founded in 1871. Based in Chile, CorpBanca also participates in Colombia and Panama. It also has a branch in New York and a representative office in Madrid. Its total consolidated assets are US$36 billion approximately and the equity totaled US$3.4 billion. Focused on large and medium companies and individuals, CorpBanca offers universal bank products. Its remarkable performance in the past 18 years has allowed consolidating CorpBanca as the fourth largest private bank in Chile. In 2012 CorpBanca started the process of regionalization with the acquisition of two banks in Colombia, becoming the first Chilean bank to have banking subsidiaries abroad.

As of May 31, 2014, according to the Chilean Superintendency of Banks, CorpBanca was the fourth largest private bank in Chile in terms of the overall size of its customer loan portfolio (12.0% market share on a consolidated basis and 7.5% market share among private banks on an unconsolidated basis only taking into account its operations in Chile).

At the same date, according to the Colombian Superintendency of Finance, CorpBanca Colombia and Helm Bank combined operations were the sixth largest bank in Colombia in terms of total assets and in terms of total loans and also the sixth largest bank in Colombia in terms of total deposits, as reported under local regulatory and accounting principles.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "believe", "expect", "plan", "intend", "forecast", "target", "project", "may", "will", "should", "could", "estimate", "predict" or similar words suggesting future outcomes or language suggesting an outlook. Forward-looking statements and information are based on current beliefs as well as assumptions made by and information currently available to CorpBanca concerning anticipated financial performance, business prospects, strategies and regulatory developments. Although management considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks that predictions, forecasts, projections and other forward-looking statements will not be achieved. We caution readers not to place undue reliance on these statements as a number of important factors could cause the actual results to differ materially from the beliefs, plans, objectives, expectations and anticipations, estimates and intentions expressed in such forward-looking statements. More information on potential factors that could affect CorpBanca's financial results is included from time to time in the "Risk Factors" section of CorpBanca's Annual Report on Form 20-F for the fiscal year ended December 31, 2013, filed with the SEC. Furthermore, the forward-looking statements contained in this press release are made as of the date of this press release and CorpBanca does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

CORPBANCA CONTACT Investor Relations, CorpBanca Santiago, Chile Phone: +56 (2) 2660-2555 IR@corpbanca.cl

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 17

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 311

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 35

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 0

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Preeclampsia: Key Insights for Expecting Parents

Updated Category News Views 46

Preeclampsia: Essential Insights for Expecting Parents Preeclampsia is a significant condition that often raises concerns among expecting parents. It manifests as a dangerous form of high blood pressure during pregnancy and can also surface postpartum. Understanding this condition is vital for ensuring the health and safety of both mother and child during this crucial...

Continue Reading
DTE Energy Enhances Reliability with Smart Grid Technology

Updated Category News Views 240

DTE Energy's Progress with Smart Grid Technology DTE Energy (NYSE:DTE) has announced impressive strides in enhancing energy reliability through its cutting-edge smart grid technology. This initiative has successfully prevented nearly 5,000 power interruptions and saved over 1.8 million outage minutes for customers this year, highlighting the technology's role in ensuring...

Continue Reading
Key Insider Transactions in Major US Companies Unveiled

Updated Category News Views 270

Significant Insider Trading Activities This article sheds light on the notable insider buying and selling events reported recently, reflecting the movements within major US stocks. Major Insider Purchases Berkshire Hathaway Inc. (NYSE: BRKa) has made headlines by increasing its stake in Verisign Inc. (NASDAQ: VRSN). Under the leadership of Warren E. Buffett, the company...

Continue Reading
Hull Tactical's Latest Research Paper Enhances Market Predictions

Updated Category News Views 135

Hull Tactical Releases Innovative Academic Research The Hull Tactical team is excited to unveil its latest academic paper, titled Micro Alphas, co-authored by a talented group including Blair Hull, Petra Bakosova, Francois Cocquemas, Euan Sinclair, and Petri Fast. This research introduces a fresh framework that focuses on utilizing weak yet collectively informative...

Continue Reading
Cyrano Therapeutics and KYORIN Join Forces for Smell Loss Treatment

Updated Category News Views 138

Cyrano Therapeutics and KYORIN Collaboration Overview Cyrano Therapeutics, a pioneer in regenerative medicine, has taken a significant step forward in addressing the challenge of post-viral loss of smell. The company has entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. to develop CYR-064, a promising treatment candidate specifically designed for those...

Continue Reading